Search results for "liver neoplasm"

showing 10 items of 740 documents

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.

2010

Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomized controlled trials (RCTs) of new therapeutic approaches; however, survival of patients in the absence of treatment is highly variable, and prognostic factors influencing outcomes are incompletely defined. The aims of this meta-analysis were to estimate the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of palliative treatments, and to identify prognostic factors. RCTs evaluating therapies for HCC with placebo or no-treatment arms were identified on MEDLINE through April 2009. Data were combined in a random effect model. Primary outcomes were 1-year and 2-year s…

medicine.medical_specialtyCarcinoma Hepatocellularlaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemoembolization TherapeuticSurvival rateNeoplasm StagingRandomized Controlled Trials as TopicHepatologyPerformance statusbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseConfidence intervalSurgerySurvival RateMeta-analysisHepatocellular carcinomaRegression AnalysisLiver cancerbusinessPublication BiasHepatology (Baltimore, Md.)
researchProduct

Expression of Wild-Type and Variant Estrogen Receptor Alpha in Liver Carcinogenesis and Tumor Progression.

2011

Although estrogen receptors (ERs) are expressed in human hepatocellular carcinoma (HCC), several clinical trials have failed to demonstrate the efficacy of antiestrogen treatment in HCC patients. Recently, the identification of several ER splicing variants has enlightened the complex nature of estrogen signaling in peripheral tissues; this may help understanding estrogen role in either nontumoral or malignant nonclassical target organs, including liver. In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reacti…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEstrogen receptorBiologyBiochemistryAromataseCell Line TumorInternal medicineGene OrderGeneticsmedicineHumansRNA MessengerneoplasmsMolecular BiologyLiver NeoplasmsEstrogen Receptor alphaWild typeExonsHep G2 Cellsmedicine.diseaseAntiestrogenGene Expression Regulation NeoplasticReverse transcription polymerase chain reactionAlternative SplicingCell Transformation NeoplasticEndocrinologyLiverEstrogenTumor progressionHepatocellular carcinomaCancer researchMolecular MedicineEstrogen receptor alphaLiver carcinogenesis Estrogen receptors tumor progressionBiotechnology
researchProduct

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

2019

BACKGROUND: The recurrence of hepatocellular carcinoma (HCC) is the strongest survival-limiting factor after liver transplantation (LT) in patients with HCC. In the face of donor organ shortage, it is necessary to identify factors associated with HCC recurrence in order to maximize the utility of the available grafts. OBJECTIVE: To study the phenomenon of HCC recurrence after LT at a European transplantation centre over the past 20 years. METHODS: Data from 304 HCC patients who underwent LT were prospectively recorded. Clinical and pathological factors were assessed for their association with recurrence. RESULTS: Fifty-one patients (16.8%) had HCC recurrence after LT. Patients exceeding the…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentEconomic shortageLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansIn patientneoplasmsProportional Hazards Modelsbusiness.industryLiver NeoplasmsGastroenterologyOriginal Articlesmedicine.diseasePrognosisdigestive system diseasesLiver TransplantationTransplantationEuropeTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessLiver cancer
researchProduct

Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver re…

2016

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentTreatment outcomeResection03 medical and health sciences0302 clinical medicineText miningResectable Hepatocellular CarcinomamedicinePathologic ResponseHepatectomyHumansChemoembolization TherapeuticRetrospective StudiesHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRadiologyHepatectomyNeoplasm Recurrence LocalbusinessHepatobiliarypancreatic diseases international : HBPD INT
researchProduct

"Pure" large cell neuroendocrine carcinoma of the gallbladder. Report of a case and review of the literature

2016

Primary Neuroendocrine Tumours (NETs) of the gallbladder are rare. Among all NETs of the gallbladder, large cell neuroendocrine carcinoma (LCNEC) is exceedingly rare. In most of the cases LCNECs are combined with other histological components. We reviewed clinical presentation and management of all patients with "pure" LCNEC from published literature since the first case was published in 2000, as well as one patient from our experience. Only 7 cases of "pure" LCNEC has been described in the last 15 years, our case is the eighth. The diagnosis of gallbladder NETs is rarely made preoperatively since the presentation generally consists of non-specific symptoms including upper abdominal pain, d…

medicine.medical_specialtyCarcinoma; Gallbladder; Large cell neuroendocrine carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; SurgeryGallbladder Neuroendocrine Carcinomamedicine.medical_treatmentGallstonesAdenocarcinomaNeuroendocrine tumorsSettore MED/08 - Anatomia PatologicaDiagnosis Differential03 medical and health sciences0302 clinical medicineNeuroendocrine tumourmedicineCarcinomaHepatectomyHumansAgedIncidental Findingsbusiness.industryLarge cell neuroendocrine carcinomaGallbladderGeneral surgeryLiver NeoplasmsCarcinomaGallbladderGeneral MedicineGallstonesmedicine.diseaseCarcinoma NeuroendocrineNeuroendocrine TumorsSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureCholecystectomy Laparoscopic030220 oncology & carcinogenesisNeuroendocrine carcinomaCarcinoma Large CellFemaleGallbladder Neoplasms030211 gastroenterology & hepatologySurgeryCholecystectomyRadiologyGallbladder NeoplasmDifferential diagnosisbusiness
researchProduct

Moderne Diagnostik zystischer Leberläsionen und Hämangiome

2015

Clinical issue: Cystic liver lesions incorporate a broad heterogeneous group of mostly benign but also malignant abnormalities. The radiological aim is the non-invasive diagnosis with the use of different imaging modalities to determine the type of lesion.Standard radiological methods: The common generally asymptomatic incidental findings of cystic lesions on ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) must be classified on the basis of specific imaging features. Such a differentiation is essential because the clinical consequences and the appropriate therapy can vary depending on the underlying pathology. Due to the morphological overlap of many cystic lesions…

medicine.medical_specialtyCholangiopancreatography Magnetic ResonanceDiagnosis DifferentialMagnetic resonance imagingX ray computedImaging procedureClinical informationMedicineRadiology Nuclear Medicine and imagingUltrasonographyGynecologyPathogenetic mechanismNon-invasive diagnosibusiness.industryImaging ProceduresImage enhancementImage EnhancementCystTomography x ray computedLiver NeoplasmUltrasonographyClinical informationHemangiomaTomography X-Ray ComputedbusinessHumanDer Radiologe
researchProduct

Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-ana…

2020

Background Cholangiocarcinoma is a cancer with poor prognosis. The detection of risk factors is fundamental to identify subjects at higher risk of cholangiocarcinoma. Nonalcoholic fatty liver disease (NAFLD) represents a leading cause of chronic liver disease worldwide. Recent data suggested that NAFLD increases the risk of cholangiocarcinoma development. However, it is necessary to better explain the strength of association between NAFLD and cholangiocarcinoma. Methods A systematic research of current case-control, cohort, clinical trial and meta-analysis on the main electronic databases was made. A recent systematic review was recognized. We performed cumulative meta-analyses with sensiti…

medicine.medical_specialtyChronic liver diseasedigestive systemGastroenterologyCholangiocarcinoma03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansIntrahepatic CholangiocarcinomaHepatologybusiness.industryConfoundingLiver NeoplasmsGastroenterologyOdds ratiomedicine.diseasedigestive system diseasesConfidence intervalClinical trialBile Ducts IntrahepaticBile Duct Neoplasms030220 oncology & carcinogenesisMeta-analysisliver Intrahepatic Cholangiocarcinoma extrahepatic Cholangiocarcinoma030211 gastroenterology & hepatologybusiness
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

2020

The rising prevalence of the metabolic syndrome has led to an increase of non-alcoholic fatty liver disease (NAFLD), and its progressive-inflammatory form called non-alcoholic steatohepatitis (NASH). In recent years, NAFLD and NASH have become major risk factors for developing liver cirrhosis and hepatocellular carcinoma (HCC). In this case, we report a 46-year-old patient with type 2 diabetes mellitus and metabolic comorbidities including obesity and arterial hypertension, who was referred because of rising liver enzymes. After clinical and diagnostic evaluation, the patient was diagnosed with NASH-associated liver cirrhosis, Child-Pugh stage B. A normal blood sugar level was difficult to …

medicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityLiver transplantationChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineFatal OutcomeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineObesityMetabolic Syndromebusiness.industryFatty liverLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesDiabetes Mellitus Type 2Hepatocellular carcinomaHypertension030211 gastroenterology & hepatologyMetabolic syndromeSteatohepatitisInsulin ResistancebusinessZeitschrift fur Gastroenterologie
researchProduct

Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells

2009

Human hepatocellular carcinoma (HCC) is associated with high mortality rates, being the third most common cause of cancer death worldwide. Although estrogens have been implicated in HCC, their potential role in development and/or progression of this malignancy remains unclear. In this study we investigated mRNA and protein expression of aromatase (Aro) and amphiregulin (AREG) in relation to estrogen receptors (ERs), in HepG2, Huh7, and HA22T human malignant liver cell lines, using RT-PCR and Western blot analyses. Aro expression was significantly higher (approximately 13-fold, P= 0.003) in HepG2 cells than in Huh7 cells, while no Aro expression could be detected in HA22T cells. Interestingl…

medicine.medical_specialtyEGF Family of ProteinsBlotting WesternEstrogen receptorAmphiregulinGeneral Biochemistry Genetics and Molecular BiologyAromataseHistory and Philosophy of ScienceAmphiregulinWestern blotInternal medicineCell Line TumormedicineHumansEstrogen receptors hepatocellular carcinoma amphiregulinAromataseDNA PrimersGlycoproteinsbiologymedicine.diagnostic_testBase SequenceReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceLiver cellLiver NeoplasmsEstrogen Receptor alphamedicine.diseasedigestive system diseasesBlotEndocrinologyCell cultureHepatocellular carcinomabiology.proteinCancer researchIntercellular Signaling Peptides and Proteins
researchProduct